FrancophonIA/ELRC3.0 huggingface dataset:
English: Subjects (N=135) had a median age of 51 years (range: 19 to 70); 63,7% were treatment-naïve, 17.0% were prior pegIFN/RBV null responders, 6.7% were prior pegIFN/RBV partial responders, 12.6% were prior pegIFN/RBV relapsers; 65.2%were male; 8.9% were Black, 69.6% had baseline HCV RNA levels at least 800,000 IU/mL; 6.7% had bridging fibrosis (F3).
Icelandic: Miðgildi aldurs (N=135) var 51 ár (á bilinu: 19 til 70); 63,7% höfðu ekki fengið meðferð áður, 17,0% fengu enga svörun í fyrri pegIFN/RBV meðferð, 6,7% fengu hlutasvörun í fyrri pegIFN/RBV meðferð, 12,6% fengu bakslag eftir fyrri pegIFN/RBV meðferð, 65.2% voru karlkyns; 8,9% voru af svörtum kynstofni; 69,6% voru með HCV RNA grunnlínuviðmið a.m.k.
English: What you need to know before you take Viekirax Do not take Viekirax
Icelandic: Áður en byrjað er að nota Viekirax Ekki má nota Viekirax:
English: The maximum daily dose of rosuvastatin should be 10 mg (see section 4.4).
Icelandic: (0,57-0,74) Daglegur hámarksskammtur af rosuvastatini skal vera 10 mg (sjá kafla 4.4).
English: Mechanism: CYP3A inhibition by ritonavir
Icelandic: Verkunarháttur: ritonavir hamlar CYP3A
English: Due date
Icelandic: NÚKLEÓSÍÐHEMLAR
English: Clinical monitoring and dose reduction is recommended for angiotensin receptor blockers when coadministered with Viekirax with or without dasabuvir.
Icelandic: Mælt er með klínísku eftirliti og skammtaminnkun þegar angiotensinviðtakahemlar eru gefnir samhliða Viekirax með eða án dasabuvirs.
English: Viekirax and dasabuvir with RBV 12-week arm
Icelandic: Viekirax og dasabuvir með RBV 12-vikna armur
English: No dose adjustment is necessary for raltegravir or Viekirax with or without dasabuvir.
Icelandic: Skammtaaðlögun er ekki nauðsynleg fyrir raltegravir eða Viekirax með eða án dasabuvirs.
English: If you take more Viekirax than you should
Icelandic: Ef tekinn er stærri skammtur en mælt er fyrir um
English: Fexofenadine
Icelandic: SVEPPALYF
English: Not studied; No interaction expected when gemfibrozil is used in combination with Viekirax without dasabuvir.
Icelandic: Engin milliverkun áætluð þegar gemfibrozil er notað samhliða Viekirax án dasabuvirs.
English: 250 mg single dose
Icelandic: Carisoprodol 250 mg stakur skammtur
English: Mechanism: CYP2C19 induction by ritonavir.
Icelandic: CYP2C19 örvun af völdum ritonavirs
English: The absolute bioavailability of ombitasvir and paritaprevir was approximately 50% when administered with food as Viekirax.
Icelandic: 50% þegar lyfin voru gefin með fæðu sem Viekirax.
English: Viekirax is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults (see sections 4.2, 4.4, and 5.1).
Icelandic: C (CHC) hjá fullorðnum (sjá kafla 4.2, 4.4 og 5.1).
English: Mechanism: CYP2C19 induction and CYP3A4 inhibition by ritonavir
Icelandic: CYP2C19 og hamlar CYP3A4
English: Similar effect expected as observed with Viekirax + dasabuvir.
Icelandic: Svipuð áhrif og sáust með Viekirax + dasabuvir.
English: Expected: ↑ ergot derivatives
Icelandic: ↑ ergot afleiður
English: Mechanism: CYP3A4 induction by rifampicin.
Icelandic: CYP3A4 örvun af völdum rifampicins
English: Viekirax and dasabuvir with RBV 12 weeks
Icelandic: Viekirax og dasabuvir með RBV 12 vikur
English: NA No dose adjustment needed for sofosbuvir when administered with Viekirax with or without dasabuvir.
Icelandic: Á ekki við Skammtaaðlögun er ekki nauðsynleg fyrir sofosbuvir þegar það er gefið samhliða Viekirax með eða án dasabuvirs.
English: Hepatic impairment
Icelandic: Við geðklofa
English: Based on population pharmacokinetic analysis of data from Phase 3 clinical studies, female subjects would have approximately 55% higher, 100% higher and 15% higher ombitasvir, paritaprevir and ritonavir exposures than male subjects.
Icelandic: 55% hærri útsetningu fyrir ombitasviri, 100% hærri fyrir paritapreviri og 15% hærri fyrir ritonavir heldur en karla.
English: ↑ dabigatran etexilate
Icelandic: Dabigatran etexilat
English: Dose normalized cyclosporine ratios are shown for interaction with Viekirax with or without dasabuvir.
Icelandic: Sýnd eru stöðluð skammtahlutföll fyrir ciclosporin vegna milliverkana við Viekirax með eða án dasabuvirs.
English: NA No dose adjustment required for cyclobenzaprine; increase dose if clinically indicated.
Icelandic: Á ekki við Skammtaaðlögun er ekki nauðsynleg fyrir cyclobenzaprin; auka skal skammt ef það er klínískt nauðsynlegt.
English: Viekirax without dasabuvir ciclosporin ombitasvir
Icelandic: Viekirax án dasabuvirs ciclosporin ombitasvir
English: Viekirax and dasabuvir with weight-based ribavirin for 12 or 24 weeks
Icelandic: Viekirax og dasabuvir með ribavirini skammtað eftir þyngd í 12 eða 24 vikur
English: Contraceptive medicines that contain ethinyloestradiol cannot be used in combination with Viekirax.
Icelandic: Ekki má nota getnaðarvarnarlyf sem innihalda ethinýlestradíól samhliða Viekirax.
English: Frequency
Icelandic: Víxlónæmi
English: Expected
Icelandic: Búist við
English: Clinical Comments inhibition by paritaprevir, ombitasvir and dasabuvir.
Icelandic: Klínískar athugasemdir að paritaprevir, ombitasvir og dasabuvir hamli UGT.
English: MUSCLE RELAXANTS Carisoprodol
Icelandic: Cyclobenzaprin, carisoprodol
English: Side effects when taking Viekirax with dasabuvir and ribavirin:
Icelandic: Aukaverkanir þegar Viekirax er tekið með dasabuviri og ribavirini:
English: ANGIOTENSIN RECEPTOR BLOCKER Valsartan
Icelandic: ANGIOTENSINVIÐTAKAHEMLAR Valsartan
English: Dose normalized tacrolimus ratios are shown for interaction with Viekirax with or without dasabuvir.
Icelandic: Sýnd eru stöðluð skammtahlutföll tacrolimus vegna milliverkana við Viekirax með og án dasabuvirs.
English: Subjects had a median age of 56 years (range: 32 to 81); 50% were treatment-naïve, 28% were prior pegIFN/RBV null responders; 10% were prior pegIFN/RBV partial responders, 13% were prior pegIFN/RBV relapsers; 70% were male; 17% were Black; 73% had baseline HCV RNA levels of at least 800,000 IU per mL; 17% had platelet counts of less than 90 x 109 per L; and 4% had albumin less than 3.5 mg per dL.
Icelandic: Miðgildi aldurs var 56 ár (á bilinu: 32 til 81); 50% höfðu ekki fengið meðferð áður, 28% fengu enga svörun í fyrri pegIFN/RBV meðferð, 10% fengu hlutasvörun í fyrri pegIFN/RBV meðferð, 13% fengu bakslag eftir fyrri pegIFN/RBV meðferð, 70% voru karlkyns; 17% voru af svörtum kynstofni; 73% voru með HCV RNA upphafsgildi a.m.k.
English: Medicinal products metabolised by CYP3A4
Icelandic: Hömlun á CYP3A4
English: Medicines you must not take with Viekirax Medicine or active substance
Icelandic: Lyf sem ekki má taka með Viekirax
English: TURQUOISE-III: treatment-naïve or pegIFN + RBV-experienced with compensated cirrhosis Design:
Icelandic: TURQUOISE III: án þess að hafa áður fengið meðferð eða eftir að hafa fengið meðferð með pegIFN+RBV, með einkennalausa skorpulifur
English: Extreme caution must be taken to avoid pregnancy in female patients and female partners of male patients when Viekirax is taken in combination with ribavirin.
Icelandic: Gæta verður sérstaklega mikillar varúðar til að koma í veg fyrir þungun hjá konum hvort sem þær eru sjúklingar eða makar karlmanna sem taka Viekirax samhliða ribavirini.
English: Viekirax with or without dasabuvir coadminstered with or without weight-based ribavirin for 12 or 24 weeks
Icelandic: Viekirax og dasabuvir með eða án ribavirins í 12 eða 24 vikur
English: Treated subjects (N=380) had a median age of 58 years (range: 21 to 71); 42.1% were treatment-naïve, 36.1% were prior pegIFN/RBV null responders; 8.2% were prior pegIFN/RBV partial responders, 13.7% were prior pegIFN/RBV relapsers; 70.3% were male; 3.2% were Black; 14.7% had platelet counts of less than 90 x 109/L; 49.7% had albumin less than 40 g/L; 86.1% had baseline HCV RNA levels of at least 800,000 IU/mL; 24.7% had a history of depression or bipolar disorder; 68.7% had HCV genotype 1a infection, 31.3% had HCV genotype 1b infection.
Icelandic: 21 til 71); 42,1% höfðu ekki fengið meðferð áður; 36,1% sýndu enga svörun við fyrri meðferð pegIFN/RBV; 8,2% sýndu hlutasvörun við fyrri meðferð pegIFN/RBV og 13,7% fengu bakslag eftir fyrri meðferð pegIFN/RBV; 70,3% voru karlkyns; 3,2%% voru af svörtum kynstofni; 14,7% voru með blóðflagnatalningu undir 90 x 109/l; 49,7% voru með albumin undir 40 g/l; 86,1% voru með HCV RNA grunngildisviðmið a.m.k.
English: randomised, global multicentre, double-blind, regimen-controlled
Icelandic: slembiröðuð, alþjóðleg, fjölsetra tvíblind samanburðarrannsókn
English: Mechanism: OATP1B inhibition by paritaprevir and BCRP inhibition by paritaprevir, ritonavir or dasabuvir.
Icelandic: Paritaprevir hamlar OATPB1 og paritaprevir, ritonavir eða dasabuvir hamla BCRP.
English: Pravastatin 10 mg once daily
Icelandic: 10 mg einu sinni á sólarhring
English: Viekirax + dasabuvir omeprazole
Icelandic: Viekirax + dasabuvir omeprazol
English: Following dosing of ombitasvir/paritaprevir/ritonavir with or without dasabuvir, mean plasma half-life of ombitasvir was approximately 21 to 25 hours.
Icelandic: Eftir gjöf ombitasvirs/paritaprevirs/ritonavirs, með eða án dasabuvirs var meðalhelmingunartími ombitasvirs í plasma u.þ.b.
English: AbbVie SA Belgique/Belgien
Icelandic: Belgique/Belgien Tél/Tel:
English: Mechanism: CYP3A4/Pgp inhibition by conivaptan and paritaprevir/ ritonavir/ombi tasvir
Icelandic: Conivaptan og paritaprevir/ri tonavir/ombit asvir hamla CYP3A4/Pgp
English: ↑ norgestrel ↑ nor elgestromine ombitasvir paritaprevir
Icelandic: ↑ nor elgestromi n ombitasvir
English: Viekirax + dasabuvir rosuvastatin
Icelandic: Viekirax + dasabuvir pravastatin
English: Treatment-naïve, without cirrhosis SAPPHIRE I
Icelandic: Hafa ekki áður fengið meðferð, án skorpulifrar SAPPHIRE I
English: (≤25% difference in the Least Square Means ratio) for Viekirax with or without dasabuvir, unless otherwise noted.
Icelandic: Umfang milliverkunar þegar Viekirax er gefið með lyfjum í töflu 2 er svipað (≤25% munur á hlutfalli meðaltali minnstu fervika) fyrir Viekirax hvort sem er með eða án dasabuvirs, nema annað sé tekið fram.
English: AGATE-1 -treatment-naïve or pegIFN +RBV experienced patients with compensated cirrhosis
Icelandic: AGATE 1 - án þess að hafa fengið meðferð áður eða eftir að hafa fengið meðferð með pegIFN+RBV með einkennalausa skorpulifur
English: Dose decrease and clinical monitoring of calcium channel blockers is recommended when coadministered with Viekirax with and without dasabuvir.
Icelandic: Mælt er með skammtaminnkun og klínísku eftirliti þegar kalsíumgangalokar eru gefnir samhliða Viekirax með eða án dasabuvirs.
English: HCV Genotype 1b Viekirax and dasabuvir
Icelandic: + RBV Hópur B: Viekirax og dasabuvir
English: DIURETICS Furosemide
Icelandic: Furosemid
English: Treated subjects (N=179) had a median age of 57 years (range: 26 to 70); 35.2% were prior pegIFN/RBV null responders; 28.5% were prior pegIFN/RBV partial responders, and 36.3% were prior pegIFN/RBV relapsers; 54.2% were male; 3.9% were Black; 12.8% had a history of depression or bipolar disorder; 87.7% had baseline HCV RNA levels of at least 800,000 IU/mL; 17.9% had portal fibrosis (F2) and 14.0% had bridging fibrosis (F3).
Icelandic: Miðgildi aldurs meðhöndlaðra einstaklinga (N=179) var 57 ár (á bilinu: 26 til 70); 35,2 sýndu enga svörun við fyrri meðferð pegIFN/RBV; 28,5% sýndu hlutasvörun við fyrri meðferð pegIFN/RBV og 36,3% fengu bakslag eftir fyrri meðferð pegIFN/RBV; 54,2% voru karlkyns; 3,9%% voru af svörtum kynstofni; 12,8% höfðu sögu um þunglyndi eða geðhvarfasýki; 87,7% voru með HCV RNA við grunngildi a.m.k.
English: Adverse drug reactions identified with Viekirax in combination with dasabuvir with and without ribavirin
Icelandic: Tafla 3. Aukaverkanir sem hafa komið fram með Viekirax samhliða dasabuviri, með og án ribavirins
English: Expected in CYP2C19 Poor Metabolisers:
Icelandic: Áætlað fyrir einstaklinga með lítil umbrot CYP2C19:
English: Pitavastatin Mechanism: OATP1B inhibition by paritaprevir
Icelandic: Paritaprevir hamlar OATP1B
English: THYROID HORMONES
Icelandic: SKJALDKIRTILSHORMÓN
English: ANTIPSYCHOTICS
Icelandic: LYFJAFRÆÐILEGAR
English: In patients with renal or hepatic impairment, use of colchicine with Viekirax with or without dasabuvir is contraindicated (see sections 4.3 and 4.5).
Icelandic: Ekki skal gefa sjúklingum með skerta nýrna- eða lifrarstarfsemi colchicin með Viekirax með eða án dasabuvirs (sjá kafla 4.3 og 4.5).
English: HIV protease inhibitors other than atazanavir and darunavir (e.g., indinavir, saquinavir, tipranavir, lopinavir/ritonavir) are contraindicated (see section 4.3).
Icelandic: Ekki skal nota aðra HIV próteasa hemla en atazanavir og darunavir (t.d. indinavir, saquinavir, tipranavir, lopinavir/ritonavir).
English: Treatment-naïve Without RBV
Icelandic: Annað - engin svörun við pegINF/RBV
English: Mechanism: P-gp inhibition by paritaprevir, ritonavir and dasabuvir.
Icelandic: Verkunarháttur: erythromycin, paritaprevir, ritonavir og dasabuvir hamla
English: Significant teratogenic and/or embryocidal effects have been demonstrated in all animal species exposed to ribavirin; therefore, ribavirin is contraindicated in women who are pregnant and in the male partners of women who are pregnant.
Icelandic: Sýnt hefur verið fram á marktæk vanskapandi og/eða fósturvísiseyðandi áhrif hjá öllum dýrategundum sem voru útsettar fyrir ribavirini.
English: Viekirax + dasabuvir atazanavir ombitasvir paritaprevir
Icelandic: Viekirax + dasabuvir atazanavir dasabuvir
English: Esomeprazole Lansoprazole Mechanism: CYP2C19 induction by ritonavir.
Icelandic: örvun CYP2C19 af völdum ritonavirs
English: Dose normalized sirolimus ratios are shown for interaction with Viekirax + dasabuvir.
Icelandic: Sýnd eru stöðluð skammtahlutföll fyrir sirolimus vegna milliverkana við Viekirax + dasabuvir.
English: ↑ fusidic acid
Icelandic: Við ofnæmiskvefi
English: What Viekirax looks like and contents of the pack
Icelandic: Lýsing á útliti Viekirax og pakkningastærðir
English: Clinical Comments inhibition of OATP1B1/B3 and CYP3A by atazanavir and CYP3A by the additional dose of ritonavir.
Icelandic: OATP1B1/B3 og CYP3A.
English: Note: Doses used for Viekirax and dasabuvir were: ombitasvir 25 mg, paritaprevir 150 mg, ritonavir 100 mg, once daily and dasabuvir 400 mg twice daily or 250 mg twice daily.
Icelandic: 25 mg, paritaprevir 150 mg, ritonavir 100 mg, einu sinni á sólarhring og dasabuvir 400 mg tvisvar á sólarhring eða 250 mg tvisvar á sólarhring.
English: Treated subjects (N=394) had a median age of 54 years (range: 19 to 71); 49.0% were prior pegIFN/RBV null responders; 21.8/% were prior pegIFN/RBV partial responders, and 29.2% were prior pegIFN/RBV relapsers; 57.6% were male; 8.1% were Black; 20.6% had a history of depression or bipolar disorder; 87.1% had baseline HCV RNA levels of at least 800,000 IU per mL; 17.8% had portal fibrosis (F2) and 14.5% had bridging fibrosis (F3); 58.4% had HCV genotype 1a infection; 41.4% had HCV genotype 1b infection.
Icelandic: Miðgildi aldurs meðhöndlaðra einstaklinga (N=394) var 54 ár (á bilinu: 19 til 71); 49,0% sýndu enga svörun við fyrra pegIFN/RBV; 21,8% sýndu svörun að hluta við fyrra pegIFN/RBV og 29,2% fengu bakslag við fyrra pegIFN/RBV; 57,6% voru karlkyns; 8,1% voru af svörtum kynstofni; 20,6% höfðu sögu um þunglyndi eða geðhvarfasýki; 87,1% voru með HCV RNA grunnlínuviðmið a.m.k.
English: Mechanism: CYP3A4 induction by carbamazepine
Icelandic: CYP3A4 örvun af völdum carbamazepin s.
English: Hepatic decompensation and hepatic failure
Icelandic: Við óeðlilegum hjartslætti eða malaríu
English: Clinical trials in subjects with genotype 4 chronic hepatitis C
Icelandic: C af arfgerð 4-með einkennalausa skorpulifur
English: Use with caution.
Icelandic: Tilgangur með lyfinu
English: Mechanism: CYP3A4 induction apalutamide enzalutamide or mitotane.
Icelandic: Verkunarháttur: apalutamid, enzalutamid eða mitotan hamla CYP3A4
English: Pharmacokinetic steady state for the combination is achieved after approximately 12 days of dosing.
Icelandic: Jafnvægi lyfjahvarfa fyrir samsetninguna næst eftir u.þ.b. 12 daga skömmtun.
English: 800/100 mg once daily
Icelandic: 300/100 mg
English: Dronedarone
Icelandic: Conivaptan
English: These metabolites are not expected to have antiviral activity.
Icelandic: Ekki er búist við að þessi umbrotsefni hafi veiruhamlandi virkni.
English: CYP3A4 inhibition by ritonavir and increase in paritaprevir exposures may be due to OATP/BCRP/ P-gp inhibition by ciclosporin.
Icelandic: CYP3A4 og meiri útsetning paritaprevirs getur stafað af því að ciclosporin hamlar
English: Clinical Comments raltegravir exposures may be due to UGT1A1 inhibition by paritaprevir, ombitasvir.
Icelandic: Aukin útsetning fyrir raltegraviri getur verið vegna þess að paritaprevir, ombitasvir og dasabuvir hamla
English: HCV ANTIVIRALS Sofosbuvir
Icelandic: HCV VEIRUHAMLANDI LYF
English: Similarly, ombitasvir was not carcinogenic in a 2-year rat study up to the highest dose tested (30 mg per kg per day), resulting in ombitasvir exposures approximately 16-fold higher than those in humans at 25 mg.
Icelandic: Ombitasvir reyndist ekki heldur krabbameinsvaldandi í 2 ára rannsókn á rottum með stærsta skammti sem prófaður var (30 mg á kg á sólarhring), sem varð til þess að útsetning fyrir ombitasviri var u.þ.b.
English: Viekirax and dasabuvir with weight-based ribavirin for 12 weeks
Icelandic: Viekirax og dasabuvir án ribavirins í 12 vikur
English: No dose adjustment needed for Viekirax with or without dasabuvir.
Icelandic: Ekki þörf á skammtaaðlögun fyrir Viekirax með eða án dasabuvirs.
English: What you need to know before you take Viekirax 3.
Icelandic: Upplýsingar um Viekirax og við hverju það er notað Áður en byrjað er að nota Viekirax Hvernig nota á Viekirax
English: Clinical Comments
Icelandic: KLÍNÍSKAR UPPLÝSINGAR
English: ↑ quinidine ↑ ranolazine
Icelandic: KG Knollstrasse
English: 0.5 mg single dose
Icelandic: Alprazolam 0,5 mg stakur skammtur
English: Breastfeeding
Icelandic: Repaglinid
English: Medicinal products metabolised by glucuronidation (UGT1A1) Paritaprevir, ombitasvir and dasabuvir are inhibitors of UGT1A1.
Icelandic: Lyf sem umbrotna fyrir tilstilli glúkúróníðtengingar (UGT1A1)
English: Design:
Icelandic: Hönnun rannsóknar:
English: 600 mg twice daily
Icelandic: Gemfibrozil 600 mg tvisvar sinnum á sólarhring
English: AMINOSALICYLATE Sulfasalazine
Icelandic: AMINOSALICYLAT
English: Ombitasvir was not carcinogenic in a 6-month transgenic mouse study up to the highest dosage tested (150 mg/kg/day), resulting in ombitasvir AUC exposures approximately 26-fold higher than those in humans at the recommended clinical dose of 25 mg.
Icelandic: Ombitasvir reyndist ekki vera krabbameinsvaldandi í 6 mánaða víxlgenarannsókn hjá músum með stærsta skammti sem prófaður var (150 mg/kg/sólarhring) sem varð til þess að útsetning
English: PHOSPHODIESTERASE-(PDE-5) INHIBITORS Sildenafil (when used for treatment of pulmonary hypertension)
Icelandic: FOSFÓDIESTERASA (PDE-5) HEMLAR
English: Clinical trial in subjects with compensated cirrhosis TURQUOISE-II - treatment-naïve or pegIFN + RBV-experienced with compensated cirrhosis Design:
Icelandic: TURQUOISE-II - án þess að hafa áður fengið meðferð eða eftir að hafa fengið meðferð með pegIFN+RBV, með einkennalausa skorpulifur
English: ↑ hydrocodo ne
Icelandic: Viekirax dasabuvir hydrocodon
English: Paritaprevir/ritonavir has shown malformations (open eye lids) at a low incidence in mice at exposures 32/8-fold higher than the exposure in humans at the recommended clinical dose.
Icelandic: Lág tíðni vansköpunar (opin augnlok) af völdum paritaprevirs/ritonavirs hefur komið fram hjá músum við útsetningu sem var 32/8-föld á við ráðlagða klíníska skammta hjá mönnum.
English: No dose adjustment is necessary for buprenorphine/naloxone and Viekirax with or without dasabuvir.
Icelandic: (2,29-4,27) Ekki er þörf á skammtaaðlögun fyrir buprenorphin/naloxon og Viekirax með eða án dasabuvirs.
English: Metabolism as well as biliary excretion of parent drug contribute to the elimination of paritaprevir.
Icelandic: Umbrot móðurlyfsins sem og útskilnaður þess með galli stuðla að brotthvarfi paritaprevirs.
English: 25 mg once daily administered in the
Icelandic: 25 mg einu sinni á sólarhring, gefið að morgni með mat
English: ANTI-DIURETIC HORMONE Conivaptan
Icelandic: Lyf sem innihalda cobicistat
English: HMG CoA REDUCTASE INHIBITOR Rosuvastatin
Icelandic: HMG CoA REDÚKTASAHEMLAR
English: Viekirax and dasabuvir without ribavirin or with weight-based ribavirin for 12 weeks Treated subjects (N=419) had a median age of 50 years (range: 19 to 70), 45.8% were male; 4.8% were Black; 9.3% had a history of depression or bipolar disorder; 73.3% had baseline HCV RNA of at least 800,000 IU/mL; 20.3% had portal fibrosis (F2) and 10.0% had bridging fibrosis (F3).
Icelandic: Miðgildi aldurs meðhöndlaðra einstaklinga (N = 419) var 50 ár (á bilinu: 19 til 70); 45,8% voru karlkyns; 4,8% voru af svörtum kynstofni; 9,3% voru með sögu um þunglyndi eða geðhvarfasýki ; 73,3% voru með HCV RNA grunngildi sem var a.m.k.
English: SN:
Icelandic: Tel:
English: No dose adjustment needed for dolutegravir when coadministered with Viekirax with or without dasabuvir.
Icelandic: Skammtaaðlögun er ekki nauðsynleg fyrir dolutegravir þegar það er gefið með Viekirax með eða án dasabuvirs.
English: Copovidone
Icelandic: Hydrocodon
English: ↔ zolpidem 0.94
Icelandic: ↑ rilpivirin 2,55
English: Ethinyloestradiolcontaining oral contraceptives are contraindicated (see section 4.3).
Icelandic: Frábending er fyrir getnaðarvarnarlyf til inntöku sem innihalda ethinýlestradíól (sjá kafla 4.3).
English: Viekirax and dasabuvir without ribavirin or with weight-based ribavirin for 12 weeks Treated subjects (N=305) had a median age of 54 years (range: 19 to 70); 65.2% were male; 11.8% were Black; 20.7% had a history of depression or bipolar disorder; 86.6% had baseline HCV RNA levels of at least 800,000 IU/mL; 18.4% had portal fibrosis (F2) and 17.7% had bridging fibrosis (F3).
Icelandic: Miðgildi aldurs meðhöndlaðra einstaklinga (N=305) var 54 ár (á bilinu: 19 til 70); 65,2% voru karlkyns; 11,8% voru af svörtum kynstofni; 20,7% höfðu sögu um þunglyndi eða geðhvarfasýki ; 86,6% voru með HCV RNA grunngildisviðmið a.m.k.
English: Astemizole Terfenadine Mechanism: CYP3A4 inhibition by ritonavir.
Icelandic: Lyf sem hamla CYP3A4 og flutningspróteinum
English: ↔ carba mazepine
Icelandic: Carbamazepin
English: Viekirax and dasabuvir with weight-based ribavirin for 12 weeks Treated subjects (N=631) had a median age of 52 years (range: 18 to 70); 54.5% were male; 5.4% were Black; 15.2% had a history of depression or bipolar disorder; 79.1% had baseline HCV RNA levels of at least 800,000 IU/mL; 15.4% had portal fibrosis (F2) and 8.7% had bridging fibrosis (F3); 67.7% had HCV genotype 1a infection; 32.3% had HCV genotype 1b infection.
Icelandic: 800.000 a.e./ml; 15,4% voru með bandvefsmyndun í vefgátt (portal fibrosis) (F2) og 8,7% voru með brúandi bandvefsaukningu (bridging fibrosis) (F3); 67,7% voru með HCV sýkingu af arfgerð 1a; 32,3% voru með HCV sýkingu af arfgerð 1b.
English: Disopyramide
Icelandic: Amlodipin
English: The magnitude of interaction was similar to that observed with Viekirax + dasabuvir.
Icelandic: Svipuð áhrif áætluð og sáust með Viekirax + dasabuvir.
English: Nifedipine Mechanism: CYP3A4 inhibition
Icelandic: Verkunarháttur: cobicistat hamlar CYP3A4
English: No dose adjustment is necessary for methadone and Viekirax with or without dasabuvir.
Icelandic: (0,87-1,01) Ekki er þörf á skammtaaðlögun fyrir methadon og Viekirax með eða án dasabuvirs.
English: Mechanism: possible CYP3A4 induction by efavirenz.
Icelandic: Efavirenz örvar hugsanlega CYP3A4.
English: NA
Icelandic: ALLS
English: Lower ribavirin dose at initiation may be appropriate.
Icelandic: 4. Í upphafi meðferðar gæti minni skammtur af ribavirini átt við.
English: Trazodone Mechanism: CYP3A4 inhibition by ritonavir.
Icelandic: Verkunarháttur: ritonavir hamlar CYP3A4.